LINCOLN PHARMACEUTICALS LTD. - 531633 - Shareholding for the Period Ended December 31, 2020
Lincoln Pharmaceuticals Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2020. For more details, kindly Click here LINCOLN PHARMACEUTICALS LTD. - 531633 - Statement Of Investor Complaints For The Quarter Ended December 2020
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- NIREN DESAIDesignation :- Company Secretary and Compliance Officer LINCOLN PHARMACEUTICALS LTD. - 531633 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Munjal Mahendrabhai Patel & PACs LINCOLN PHARMACEUTICALS LTD. - 531633 - Closure of Trading Window
It is informed that the Trading Window for dealing in securities of the Company shall remain closed from January 01, 2021 till Forty Eight Hours after the declaration of Un-Audited Financial Results of the Company for the Quarter and Nine Months Ended on December 31, 2020. LINCOLN PHARMACEUTICALS LTD. - 531633 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Kailashben Mahendrabhai Patel & PACs LINCOLN PHARMACEUTICALS LTD. - 531633 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Munjal Mahendrabhai Patel & PACs LINCOLN PHARMACEUTICALS LTD. - 531633 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation regarding loss of duplicate Share certificate pursuant to regulation 39 (3) of SEBI (LODR) Regulations, 2015 LINCOLN PHARMACEUTICALS LTD. - 531633 - Disclosure Of Related Party Transactions On Consolidated Basis Under Regulation 23(9) Of SEBI (LODR) Regulations, 2015.
Pursuant to Regulation 23 (9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the disclosure of Related Party Transactions on consolidated basis, drawn in accordance with applicable Indian Accounting Standards, for the Half Year Ended September 30, 2020. LINCOLN PHARMACEUTICALS LTD. - 531633 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Please find enclosed herewith the copies of published newspaper advertisement with respect to the Un-Audited Financial Results (Standalone and Consolidated) of the Company for the Quarter and Half Year Ended September 30, 2020. Lincoln Pharmaceuticals standalone Q2 net up 33% q-o-q
Standalone revenues from operations jumped about 22% q-o-q